Menopause hormone therapy: the truth that fear kept from you
20 years of fear over a 2002 study that was misread. We set the record straight with the science of 2026: real benefits (symptoms + bones), real risks (breast, clots), the window of opportunity, and why modern MHT has nothing in common with that of 2002. In French with English subtitles.
Watch on YouTube (full description and references) →
Read the written and sourced version of this topic →
What you will understand
For nearly twenty years, millions of women endured hot flashes, insomnia and dryness while refusing a treatment that could have relieved them. Behind that giving up: a single study, published in 2002, widely misunderstood and badly told.
This video sets the record straight. It explains where the fear comes from, what hormone therapy really does, its documented benefits for symptoms and for bone, its real risks (breast, clots) presented honestly, and the concept of the "window of opportunity" that changed the way the data are read.
It also highlights a technical development that is often ignored: modern MHT, given transdermally and combined with micronized progesterone, has little left in common with the tablet studied in 2002. That does not make it harmless or universal: prescribing it remains an individualized medical decision, which depends on symptoms, age, time since menopause and contraindications.
What the studies show
In July 2002, one arm of the vast American Women's Health Initiative study, which was testing a treatment combining estrogen and a progestin against placebo, was stopped early. The researchers had observed an increase in the risk of breast cancer, stroke and clots. Within a few months, prescriptions collapsed. The message people took away, that of a dangerous treatment, was not exactly what the study showed.
The crucial point is the age of the participants. The women included were on average 63 years old, and many were more than ten years past their menopause when they started the treatment. That is not the profile of a woman starting hormone therapy today, more likely between 50 and 55, in early menopause, to relieve symptoms. The absolute risks were also modest, and the eighteen-year follow-up of that same study found no increase in overall mortality, cardiovascular mortality or cancer mortality among the women treated for five to seven years.
From that re-reading came the timing hypothesis: the effects of the treatment on the heart and the blood vessels would depend on when it is started relative to menopause. The ELITE trial, designed to test that idea, showed that estradiol slowed the progression of arterial thickening when it was started less than six years after menopause, but not when it was started ten years or more afterwards. That is why current recommendations are built around a simple marker: the balance is most favorable before 60 or within ten years of menopause, in the absence of contraindications.
On the benefits side, two are solidly established. Hormone therapy remains the most effective option against vasomotor symptoms, which is its main recognized indication. And in the WHI study, the combined treatment reduced the risk of fractures, including hip fractures, with an improvement in bone density. To that is added, harder to quantify but real, the improvement in sleep, mood and intimate comfort that comes with relief from symptoms.
Adding nuance does not mean minimizing. On the breast, the most important distinction is the regimen: an analysis of the two WHI trials showed opposite effects depending on the formula, estrogen combined with a progestin being linked to an increase in risk, estrogen alone, prescribed to women without a uterus, being associated with a decrease. In women who start late, more than ten years after menopause or after 60, the balance becomes less favorable, with higher risks of coronary disease, stroke and clots.
One final technical point changes a great deal: the route of administration. The oral route passes through the liver, which influences coagulation, whereas the patch or the gel avoid that first liver pass. A large British study based on general practice databases compared the two routes: oral preparations were associated with an increase in the risk of venous thrombosis, transdermal preparations were not, whatever the dose.
Each of these studies is cited with its PubMed identifier in the written, sourced version of this topic.
The key points to remember
- The fear of MHT comes from a mistaken reading of a 2002 study, relayed without nuance for two decades.
- The best established benefits concern vasomotor symptoms and bone protection.
- The risks exist and must be stated honestly, in particular the risk of thrombosis and the question of the breast.
- The moment of initiation counts: the benefit-risk balance is not the same at 52 as at 70.
- Modern MHT (transdermal route + micronized progesterone) differs from the treatment studied in 2002.
- It is never self-medication or an anti-aging supplement: it is an individualized medical decision.
- The women in the 2002 study were on average 63 years old, often more than ten years past their menopause.
- The eighteen-year follow-up of that same study showed no increase in overall mortality.
- The ELITE trial observed an effect on the arteries only when the treatment was started less than six years after menopause.
- Estrogen alone and estrogen combined with a progestin do not have the same effect on the breast.
- The transdermal route was not associated with a rise in the risk of venous thrombosis, unlike the oral route.
Video chapters
The scientific sources cited
Every claim in this video rests on a verified reference. Here is the complete list, with the PubMed links.
- Rossouw JE, et al. Risks and benefits of estrogen plus progestin (WHI). JAMA. 2002 (PubMed 12117397)
- Rossouw JE, et al. Hormone therapy & cardiovascular disease by age/years since menopause. JAMA. 2007 (PubMed 17405972)
- Hodis HN, et al. Early versus Late Postmenopausal Treatment with Estradiol (ELITE). N Engl J Med. 2016 (PubMed 27028912)
- Harman SM, et al. Recently menopausal women, arterial imaging (KEEPS). Ann Intern Med. 2014 (PubMed 25069991)
- The 2022 Hormone Therapy Position Statement of NAMS. Menopause. 2022 (PubMed 35797481)
- Collaborative Group on Hormonal Factors in Breast Cancer. Type & timing of MHT & breast cancer. Lancet. 2019 (PubMed 31474332)
- Vinogradova Y, et al. HRT and risk of venous thromboembolism. BMJ. 2019 (PubMed 30626577)
- Canonico M, et al. Hormone therapy & VTE, oral vs transdermal (ESTHER). Circulation. 2007 (PubMed 17309934)
- Fournier A, et al. Different HRT & breast cancer risk (E3N). Breast Cancer Res Treat. 2008 (PubMed 17333341)
- Manson JE, et al. MHT & long-term all-cause & cause-specific mortality (WHI). JAMA. 2017 (PubMed 28898378)
- Chlebowski RT, et al. MHT & breast cancer incidence and mortality (WHI long-term). JAMA. 2020 (PubMed 32721007)
- Cauley JA, et al. Estrogen plus progestin, fracture & bone mineral density (WHI). JAMA. 2003 (PubMed 14519707)
Frequently asked questions
Does hormone therapy cause breast cancer?
The honest answer is nuanced and does not fit into one word. The excess risk depends on the type of treatment, its duration and the woman's profile, and it has to be weighed against the expected benefits for symptoms and for bone. It is precisely because the question was boiled down to a slogan in 2002 that millions of women gave up a treatment that could have suited them. The decision is taken with a doctor who knows your file.
What is the "window of opportunity"?
It is the idea that the benefit-risk balance of hormone therapy depends on when it is started: more favorable in a symptomatic woman under 60 or within the ten years following menopause, less favorable afterwards, when the absolute cardiovascular, thromboembolic and neurological risks increase.
Does MHT protect the heart?
No, and that is a frequent confusion. Hormone therapy is not indicated for cardiovascular prevention. The long-term follow-up of the Women's Health Initiative gives a neutral result on cardiovascular mortality. We devote a whole video to this question.
Why does hormone therapy frighten people so much?
Because one study was read too broadly. The WHI, published in 2002, involved women on average 63 years old, often more than ten years past their menopause: a different profile from the one it is prescribed for today. The absolute risks were modest, and the eighteen-year follow-up of that same study showed no increase in overall mortality.
Does the treatment increase the risk of breast cancer?
That depends on the regimen, and this is the essential nuance. An analysis of the two WHI trials showed opposite effects depending on the formula: estrogen combined with a progestin was linked to an increase in the risk of breast cancer, while estrogen alone, prescribed to women without a uterus, was associated with a decrease. Personal and family history weigh heavily in that assessment.
When is the balance most favorable?
Before 60, or within the ten years following menopause, in the absence of contraindications. That is what is called the timing window, born of the re-readings of the WHI and tested by the ELITE trial, which showed an effect on the arteries only when the treatment was started less than six years after menopause. Beyond that, the time factor works against the treatment.
Patch or tablet, does it change anything?
Yes, in particular for the risk of clots. The oral route passes through the liver, which influences coagulation, whereas the patch or the gel avoid that first liver pass. A large British study found an increase in the risk of venous thrombosis with oral preparations, but not with transdermal preparations, whatever the dose. The choice is up to your doctor, according to your risk factors.
Does hormone therapy protect bone?
It is one of its best documented benefits. In the WHI study, the combined treatment reduced the risk of fractures, including hip fractures, with an improvement in bone density. It is recognized on that basis for the prevention of bone loss. That is not enough to make it an indication on its own: the decision remains individualized, according to symptoms and fracture risk.